camizestrant

AstraZeneca faces a significant setback as its breast cancer pill camizestrant fails in a pivotal first-line treatment clinical trial

AstraZeneca announced on Friday that its experimental breast cancer medication, camizestrant, failed to meet its primary endpoint in the pivotal…